Diffuse large B-cell lymphoma refractory

• A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natu … Pending
  2024-511843-24-00 1 "Relapsed/refractory (R/R) diffuse large B-cell lymphoma"
• Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with … Pending
  2025-523806-34-00 4 "relapsed/refractory Large B-Cell Lymphoma"
• A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting
  2024-516869-36-00 1 2025-02-17 "Relapsed or refractory B-cell malignancies: chronic lymphocy"
• A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell … Recruiting
  2024-516234-35-00 9 2025-10-15 "Relapsed or Refractory B-Cell Malignancies"
• A trial to learn how well surovatamig (AZD0486) works and how safe it is in adults with certain blood cancers Recruiting
  2023-505789-27-00 4 2025-04-14 "Relapsed or Refractory Non-Hodgkin Lymphoma"
• A Study to Understand the Optimization of the Cytokine Release Syndrome Profile for Glofitamab along with Gemcitabine Plus Oxaliplatin in Pa … Recruiting
  2024-516791-15-00 4 2025-04-08 "Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma"
• Application of the autologous CAR T cells (Tarcidomgen Kimleucel) in the treatment of refractory and relapsed CD19+ B cell neoplasms Recruiting
  2025-520653-37-00 1 2025-01-30 "Application of the autologous CAR T cells (Tarcidomgen Kimle"
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin … Recruiting
  2023-505347-38-00 9 2022-06-13 "B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma"
• A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination w … Recruitment ended
  2023-506899-27-00 5 2021-03-25 "Relapsed or refractory diffuse large B-cell lymphoma"
• Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Recruitment ended
  2023-503384-41-00 5 2020-12-22 "Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"
• Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA … Ended
  2023-503830-27-00 4 2023-10-17 "Large B-Cell Lymphoma (LBCL)"
• A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219 Ended
  2024-515744-23-00 1 2023-02-15 "Relapsed or refractory (R/R) Acute lymphoblastic leukemia (A"
• A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) … Ended
  2024-512537-33-00 5 2019-11-28 "Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)"
• This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body a … Ended
  2023-509969-20-00 1 2017-07-24 "Part C: advanced or unresectable STs (Spain only)"

Showing 1–14 of 14 trials